50 Participants Needed

Somatic Mosaicism for Brain Tumor

JP
Overseen ByJenny Poynter, PhD
Age: < 65
Sex: Any
Trial Phase: Academic
Sponsor: Children's Oncology Group
No Placebo GroupAll trial participants will receive the active study treatment (no placebo)

What You Need to Know Before You Apply

What is the purpose of this trial?

This trial explores why children with central nervous system (CNS) tumors, such as brain tumors, might develop these conditions differently, even if they are twins. By collecting blood and saliva samples and administering questionnaires, researchers aim to uncover genetic clues that could explain these differences. The study specifically seeks twins where at least one has a CNS tumor. Families of twins who meet these criteria, including those where the affected twin has passed away but has a banked blood sample, may be eligible to join. As an unphased study, this trial offers families a unique opportunity to contribute to groundbreaking research that could lead to better understanding and treatments for CNS tumors.

Will I have to stop taking my current medications?

The trial information does not specify whether you need to stop taking your current medications. It's best to discuss this with the trial coordinators or your doctor.

Why are researchers excited about this trial?

Researchers are excited about this trial because it explores the genetic factors influencing brain tumors by analyzing biospecimens like blood and saliva from twins with central nervous system (CNS) tumors. Traditional treatments for CNS tumors usually focus on surgery, radiation, and chemotherapy, aiming to directly reduce or remove the tumor. However, this study is unique as it's not about a new drug or treatment but about gathering insights into how genetic differences impact tumor development. By understanding somatic mosaicism, or the genetic variations within the same person, scientists hope to uncover new pathways for future therapies, potentially leading to more personalized and effective treatments for brain tumors.

Who Is on the Research Team?

JP

Jenny Poynter, PhD

Principal Investigator

University of Minnesota

Are You a Good Fit for This Trial?

Inclusion Criteria

A family can participate in the program if the twin affected by a central nervous system tumor has passed away but provided an APEC14B1 blood sample.
You are a patient newly diagnosed with a central nervous system tumor or have recurrent disease and enrolled in the APEC14B1 trial.
You or your legal guardian must agree to the terms of participation, and those aged 8-17 will provide assent.
See 3 more

Timeline for a Trial Participant

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Sample Collection

Twins with CNS tumors will undergo blood and saliva DNA sample collection

1 week
1 visit (in-person)

Analysis

Sequence blood and saliva DNA samples from 25 MZ twin pairs using a panel of 94 known cancer-associated genes

Up to 18 months

Follow-up

Participants are monitored for safety and effectiveness after sample collection and analysis

4 weeks

What Are the Treatments Tested in This Trial?

Interventions

  • Biospecimen collection
  • Questionnaire Administration

How Is the Trial Designed?

1

Treatment groups

Experimental Treatment

Group I: Ancillary-CorrelativeExperimental Treatment2 Interventions

Find a Clinic Near You

Who Is Running the Clinical Trial?

Children's Oncology Group

Lead Sponsor

Trials
467
Recruited
241,000+

National Cancer Institute (NCI)

Collaborator

Trials
14,080
Recruited
41,180,000+